Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-25
1997-09-30
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514411, 514 32, 548428, 548455, 548466, 536 173, A61K 3140, A61K 3170, C07D40114, C07H 1700
Patent
active
056726180
ABSTRACT:
The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
REFERENCES:
patent: 4785085 (1988-11-01), Kaneko et al.
patent: 4808613 (1989-02-01), Kaneko et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5057614 (1991-10-01), Davis et al.
patent: 5292747 (1994-03-01), Davis et al.
patent: 5380746 (1995-01-01), Barth et al.
patent: 5481003 (1996-01-01), Gillig
Thomas et al. "Dioctanoylglycerol regulation of cytosolic CA by protein kinase C-indipendent mechanism in HIT T-15 islet cells" Diabetes vol. 40, pp. 621-627 (1991).
Dominique et al. "The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C" Jo. Biolo. Chem. vol. 266 (24) pp. 15771-15781 (1991).
Davis et al. "Preparation of 3-(3-indolyl)pyrrole-2,5-diones and analogs as protein kinase inhibitors" CA 112:98378 (1990).
Derwent Abstract 90-132947/18; (1988) DE-835842.
Derwent Abstract 92-274042/33; (1990) 90JP-314628.
Meier, e al., Tetrahedron Letters, 34:33, 5277-5280 (1993).
Wilkinson, et al., Bichem. J., 294, 335-337 (1993).
Bit, et al., J. Med. Chem., 36, 21-29 (1993).
Martiny-Baron, et al., The Journal of Biological Chemistry, 268:13, 9194-9197 (1993).
Krakowiak, et al, Synlett, 611-620, (Sep. 1993).
Mulqueen, et al., Agents Actions, 37, 85-89 (1992).
Davis, et al., J. Med. Chem., 35, 177-184 (1992).
Davis, et al., J. Med. Chem., 35, 994-1001 (1992).
Nixon, et al., Drugs Exptl. Clin. Res., 17:8, 389-393 (1991).
Davis, et al., Tetrahedron Letters, 31:36, 5201-5204 (1990).
Brenner, et al., Tetrahedron Letters, 44:10, 2887-2892 (1988).
Joyce, et al., The Journal of Organic Chemistry, 52:7, 1177-1186 (1987).
Buchdunger, et al., Proc. Natl. Acad. Sci. USA, 91, 2334-2338 (Mar. 1994).
Kobayashi, et al., The American Physiological Society, 0363-6135, H1214-H1220 (1994).
Felsenstein, et al., Neuroscience Letters, 174 173-176 (1994).
Demaerschalck, et al., Biochimica et Biophysica Acta, 1181 214-218 (1993).
Shimohama, et al., Neurology, 43 1407-1413 (1993).
Heath, Jr. William F.
McDonald, III John H.
Paal Michael
Schotten Theo
Stenzel Wolfgang
Boone David E.
Caltrider Steven P.
Chang Ceila
Collins Daniel W.
Eli Lilly and Company
LandOfFree
Protein kinase C inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase C inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2256873